Advertise
NEWSLETTER
Rapalogix Health publishes ...
Sironax Phase 2 trial reach...
Rhode Island Life Science H...
Rona Therapeutics licenses ...
IBIO-610 combined with sema...
Rapalogix Health publishes ...
Sironax Phase 2 trial reach...
Rhode Island Life Science H...
Rona Therapeutics licenses ...
IBIO-610 combined with sema...
LongevityTech.fund

FLF:SG ‘Time is ticking, and we need to do more than just lifestyle changes’

Raghav Sehgal named to ‘Forbes 30 Under 30’ for aging research

'Don’t say you are a longevity clinic if you aren't'

‘Don’t say you are a longevity clinic if you aren’t’

Young blood rising: new plasma therapy moves closer to the clinic

Young blood rising: new plasma therapy moves closer to the clinic

'Get interventions to market – and to people – faster and cheaper'

‘Get interventions to market – and to people – faster and cheaper’

Longevity investment bulletin: Juvena, eGenesis, Springs Rejuvenation and more

Petr Sramek: Now is the right time to invest in longevity

Petr Sramek and Jyothi Devakumar, PhD After successful conclusion of LongevityTech.fund, second fund is now open for business.

LongevityTech.fund II launches – now accepting new investors

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE

  • $617BN - Annual global revenue by 2045
  • $30BN+ - Invested in under 2 years
  • 3,036 - Therapeutics individually assessed